Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 180 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Multi-center Roll-over Study to Assess Long Term Safety in Endogenous Cushing's Syndrome Patients Who Have Completed a Prior Novartis-sponsored Osilodrostat Study and the Investigator Judges to Benefit From Continued Treatment
Actual Study Start Date: October 5, 2018
Estimated Primary Completion Date: February 28, 2023
Estimated Study Completion Date: October 24, 2023

Arm:
- osilodrostat